TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38746275

Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study: 38746368

Group type: EXPERIMENTAL
Intervention: Cannabis use for medical symptoms for one year
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy control group (no cannabis use)
Number of subjects: 57
Study: 38746428

Group type: EXPERIMENTAL
Intervention: Norming strategy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study: 38746736

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based support
Number of subjects: 0
Study: 38746793

Group type: EXPERIMENTAL
Intervention: Individualized nurse-led patient education programs focused on self-management of venous leg ulcers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Constructivist Grounded Theory methodology
Number of subjects: 0
Study: 38746861

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study: 38746989

Group type: COMPARATOR
Intervention: Dersimelagon 100 mg in participants with mild and moderate hepatic impairment and normal hepatic function
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dersimelagon 300 mg in participants with mild, moderate, and severe renal impairment and normal renal function
Number of subjects: 47
Study: 38747162

Group type: EXPERIMENTAL
Intervention: NBO-2h group (10 L/min for 2 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NBO-4h group (10 L/min for 4 hours)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NBO-6h group (10 L/min for 6 hours)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (1 L/min oxygen for 4 hours)
Number of subjects: 100
Study: 38747246

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 370

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: TAVI (Tricuspid AS)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Surgery (Tricuspid AS)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: TAVI (Bicuspid AS)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Surgery (Bicuspid AS)
Number of subjects: 370
Study: 38747414

Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 0
Study: 38747515

Group type: EXPERIMENTAL
Intervention: Telephone Wound Healing Questionnaire (WHQ) administered at 27 to 30 postoperative days.
Number of subjects: 1196

Group type: COMPARATOR
Intervention: In-person review by a trained clinician at 30 postoperative days.
Number of subjects: 1196
Study: 38747680

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38747749

Group type: EXPERIMENTAL
Intervention: Vitamin D3 7000 IU/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 38748236

Group type: EXPERIMENTAL
Intervention: TOETVA surgery
Number of subjects: 20
Study: 38748271

Group type: EXPERIMENTAL
Intervention: 2-[18F]FDG-PET/MRI
Number of subjects: 11
Study: 38748286

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI (ce-MRI)
Number of subjects: 7
Study: 38748319

Group type: EXPERIMENTAL
Intervention: EDP1815 (8 × 10^9 CFU daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 38748321

Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Lemborexant (both doses)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 38748345

Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Number of subjects: 237

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 237
Study: 38748431

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (n=1420) including gastric banding (n=260), vertical banded gastroplasty (n=970), gastric bypass (n=190)
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in women with baseline insulin levels above median 15.8 μIU/L
Number of subjects: 2867

Group type: EXPERIMENTAL
Intervention: Bariatric surgery in women with baseline insulin levels below median 15.8 μIU/L
Number of subjects: 2867

Group type: COMPARATOR
Intervention: Usual obesity care (control group, n=1447)
Number of subjects: 2867
Study: 38748596

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 0
Study: 38748598

Group type: EXPERIMENTAL
Intervention: Bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT)
Number of subjects: 2749

Group type: COMPARATOR
Intervention: Direct endovascular therapy (EVT) alone
Number of subjects: 2749
Study: 38748939

Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 29
Study: 38748986

Group type: EXPERIMENTAL
Intervention: Tenofovir/lamivudine/dolutegravir (TLD)
Number of subjects: 500
Study: 38749024

Group type: EXPERIMENTAL
Intervention: 6-week internet intervention program based on acceptance and commitment therapy principles
Number of subjects: 15
Study: 38749033

Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 0
Study: 38749032

Group type: EXPERIMENTAL
Intervention: Andexanet
Number of subjects: 530

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 530
Study: 38749110

Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 309

Group type: COMPARATOR
Intervention: Bevacizumab plus fluoropyrimidine
Number of subjects: 309
Study: 38749259

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2.5 μg/kg initial dose, 1 μg/kg repeat dose if needed 30 min later)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 59
Study: 38749594

Group type: EXPERIMENTAL
Intervention: Stent-Avoiding (SA) strategy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Stent-Preferred (SP) strategy
Number of subjects: 120
Study: 38749592

Group type: EXPERIMENTAL
Intervention: Low-dose prasugrel (3.75 mg/d) monotherapy
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with low-dose prasugrel and aspirin
Number of subjects: 1230
Study: 38749682

Group type: EXPERIMENTAL
Intervention: Exposure to environmental tobacco smoke (ETS)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Non-invasive or minimally invasive biospecimens collection (saliva, buccal cells, dried blood spots, urine)
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Self-reported and objective measures of ETS exposure
Number of subjects: 735
Study: 38749692

Group type: EXPERIMENTAL
Intervention: Preoperative physical activity levels (measured using the International Physical Activity Questionnaire)
Number of subjects: 204
Study: 38749694

Group type: EXPERIMENTAL
Intervention: Biologics for CRSwNP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal corticosteroids, systemic corticosteroids, and surgery
Number of subjects: 0
Study: 38749786

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (measured by peak oxygen uptake, VO2)
Number of subjects: 0
Study: 38750012

Group type: EXPERIMENTAL
Intervention: Endurance training in patients with type 2 diabetes
Number of subjects: 59

Group type: COMPARATOR
Intervention: Deconditioning in athletes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 59
Study: 38750034

Group type: EXPERIMENTAL
Intervention: Cibisatamab alone in S1
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cibisatamab with atezolizumab in S2
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Cibisatamab with obinutuzumab in S1
Number of subjects: 377
Study: 38750102

Group type: EXPERIMENTAL
Intervention: NSupple (without silymarin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSupple_Silybum (with silymarin)
Number of subjects: 0
Study: 38750142

Group type: EXPERIMENTAL
Intervention: Calcium-omics model
Number of subjects: 2457

Group type: COMPARATOR
Intervention: Agatston score
Number of subjects: 2457
Study: 38750162

Group type: EXPERIMENTAL
Intervention: diet plus phytosterol (2.6 g in 2 doses, with meals)
Number of subjects: 23

Group type: COMPARATOR
Intervention: diet
Number of subjects: 23
Study: 38750351

Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg orally once daily for up to 2 years
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 38750375

Group type: EXPERIMENTAL
Intervention: Oral hygiene training (OHt) with toothbrush and dental floss
Number of subjects: 75

Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 75
Study: 38750386

Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 6-month (PP6M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paliperidone Palmitate 3-month (PP3M)
Number of subjects: 0
Study: 38750398

Group type: EXPERIMENTAL
Intervention: Glucose analogue PET agent
Number of subjects: 0
Study: 38750416

Group type: EXPERIMENTAL
Intervention: Health mediation (HM) intervention
Number of subjects: 726

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 726
Study: 38750487

Group type: EXPERIMENTAL
Intervention: Biodegradable tracheal stents
Number of subjects: 47
Study: 38750518

Group type: EXPERIMENTAL
Intervention: Massage therapy with post-isometric relaxation exercises (Group B)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Massage therapy alone (Group A)
Number of subjects: 46
Study: 38750557

Group type: EXPERIMENTAL
Intervention: Increased psychosocial focus during children's developmental assessments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clinicians' initiatives to address psychosocial challenges
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Open communication style and trustful relationship
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Short consultation time, concerns about information use, stigma
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enquiry about family's psychosocial circumstances
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alignment of clinical and parental expectations
Number of subjects: 12
Study: 38750562

Group type: EXPERIMENTAL
Intervention: WeChat version of the Longshi Scale
Number of subjects: 115

Group type: COMPARATOR
Intervention: Paper-based version of the Longshi Scale
Number of subjects: 115
Study: 38750572

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 1887

Group type: COMPARATOR
Intervention: No statin use
Number of subjects: 1887

Group type: EXPERIMENTAL
Intervention: Initiated statin use during follow-up
Number of subjects: 1887
Study: 38750590

Group type: EXPERIMENTAL
Intervention: Bottom-up intervention approach (IG-1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Expert-based intervention (IG-2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Teacher-led intervention (IG-3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 38750621

Group type: EXPERIMENTAL
Intervention: Colovac device (CD)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Diverting loop ileostomy
Number of subjects: 342
Study: 38750712

Group type: EXPERIMENTAL
Intervention: G78717 fee-for-service physician payment for enhanced discharge planning
Number of subjects: 161328

Group type: COMPARATOR
Intervention: No financial incentive (G78717-unexposed)
Number of subjects: 161328
Study: 38750866

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg
Number of subjects: 772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772

Group type: COMPARATOR
Intervention: Vonoprazan 10 mg vs Placebo
Number of subjects: 772

Group type: COMPARATOR
Intervention: Vonoprazan 20 mg vs Placebo
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: All study arms (including both doses of vonoprazan and placebo)
Number of subjects: 772
Study: 38750870

Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg intravenously at baseline, then 90 mg subcutaneously every 8 weeks)
Number of subjects: 22
Study: 38750950

Group type: EXPERIMENTAL
Intervention: Glow! Group Prenatal Care and Support (Glow/GC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced individual prenatal care through the California Department of Public Health's Comprehensive Perinatal Services Program (CPSP/IC)
Number of subjects: 0
Study: 38751081

Group type: EXPERIMENTAL
Intervention: Preoperative predictors including self-reported central sensitisation, lower KOA grade, preoperative satisfaction, higher glycated haemoglobin, number of pain locations, and personal control
Number of subjects: 223
Study: 38751362

Group type: EXPERIMENTAL
Intervention: Lotiglipron (180 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 38751442

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1,200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2)
Number of subjects: 0
Study: 38751488

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 200

Group type: COMPARATOR
Intervention: lapatinib plus capecitabine
Number of subjects: 200
Study: 38751523

Group type: EXPERIMENTAL
Intervention: Margetuximab (15 mg/kg over at least 120 minutes) plus chemotherapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: Trastuzumab (6 mg/kg over at least 30 minutes) plus chemotherapy
Number of subjects: 123
Study: 38751579

Group type: EXPERIMENTAL
Intervention: Ashtanga Vinyasa Yoga Supta Method (AVYSM) - 12 weeks, two weekly one-hour yoga sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group - 12 weeks, protocolized course classes
Number of subjects: 0
Study: 38751852

Group type: EXPERIMENTAL
Intervention: Subfascial platelet-rich plasma (PRP) injection
Number of subjects: 92

Group type: COMPARATOR
Intervention: Enthesis needling
Number of subjects: 92
Study: 38752013

Group type: EXPERIMENTAL
Intervention: Cranberry extract (1000 mg/day)
Number of subjects: 25
Study: 38752311

Group type: EXPERIMENTAL
Intervention: Intrapartum azithromycin (2 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38752352

Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg TID
Number of subjects: 385

Group type: COMPARATOR
Intervention: Sildenafil 5 mg TID
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg TID
Number of subjects: 385
Study: 38752402

Group type: EXPERIMENTAL
Intervention: MW031
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 38752418

Group type: EXPERIMENTAL
Intervention: Inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: No therapy for 31 days
Number of subjects: 200
Study: 38752431

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion (CIVI) of Ketamine, starting at .05 mg/kg/hour and increased to .5 mg/kg/hour as needed over 5 days.
Number of subjects: 20
Study: 38752557

Group type: EXPERIMENTAL
Intervention: Healthy Families-PrEP intervention
Number of subjects: 330
Study: 38752577

Group type: EXPERIMENTAL
Intervention: CSF PDGFRβ protein levels
Number of subjects: 36
Study: 38752592

Group type: EXPERIMENTAL
Intervention: Continuous-dose abrocitinib (200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced-dose abrocitinib (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38752653

Group type: EXPERIMENTAL
Intervention: Functional Bowel Disorder (FBD)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Diagnosis of FBD at baseline
Number of subjects: 452
Study: 38752650

Group type: EXPERIMENTAL
Intervention: Immediate treatment to lower systolic blood pressure (target range, 130 to 140 mm Hg)
Number of subjects: 2404

Group type: COMPARATOR
Intervention: Usual blood-pressure management (usual-care group)
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Prehospital blood-pressure reduction in hemorrhagic stroke patients
Number of subjects: 2404

Group type: EXPERIMENTAL
Intervention: Prehospital blood-pressure reduction in cerebral ischemia patients
Number of subjects: 2404
Study: 38752802

Group type: EXPERIMENTAL
Intervention: pentavalent vaccine (DTwP-HB-Hib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hexavalent vaccine (DTaP-IPV-HB-Hib)
Number of subjects: 0
Study: 38752902

Group type: EXPERIMENTAL
Intervention: Low-pressure balloon occlusion (PCI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo inflation
Number of subjects: 51
Study: 38752951

Group type: EXPERIMENTAL
Intervention: AI-QCPHA features (including fractional flow reserve across the lesion, plaque burden, total plaque volume, low-attenuation plaque volume, and averaged percent total myocardial blood flow)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Reference model (Coronary Artery Disease Reporting and Data System and high-risk plaque)
Number of subjects: 351
Study: 38752961

Group type: EXPERIMENTAL
Intervention: Extravascular ICD
Number of subjects: 299
Study: 38752963

Group type: EXPERIMENTAL
Intervention: PolarX cryoballoon
Number of subjects: 201

Group type: COMPARATOR
Intervention: Arctic Front cryoballoon
Number of subjects: 201
Study: 38752970

Group type: EXPERIMENTAL
Intervention: Microvascular resistance reserve (MRR) <3.0 (CMD)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: MRR
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: CFR, IMR, MRR
Number of subjects: 210
Study: 38752972

Group type: EXPERIMENTAL
Intervention: QFR-guided intervention in nonculprit vessels (n = 320 nonculprit vessels)
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only treatment (n = 903 nonculprit vessels from 685 patients)
Number of subjects: 1445
Study: 38753093

Group type: EXPERIMENTAL
Intervention: Intraoperative photodynamic therapy (PDT) with 5-ALA HCl, single 200 J/cm
Number of subjects: 10
Study: 38753174

Group type: EXPERIMENTAL
Intervention: Supplemental β-carotene (15 mg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Caco-2 cell model
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High fat dairy-based meal
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Test meal matrix
Number of subjects: 7
Study: 38753273

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 38753330

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral self-help intervention
Number of subjects: 154
Study: 38753331

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) with Standard Care (SC)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard Care (SC) at NICU and postdischarge Music Therapy (MT)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) at both NICU and postdischarge
Number of subjects: 206
Study: 38753374

Group type: EXPERIMENTAL
Intervention: Antidepressant monotherapy
Number of subjects: 1944
Study: 38753415

Group type: EXPERIMENTAL
Intervention: Individualized 12-week health education program targeting an active lifestyle after oncology treatments.
Number of subjects: 150
Study: 38753416

Group type: EXPERIMENTAL
Intervention: PREMIUM-CE item bank
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: PREMIUM-CE scores
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: CAT simulations
Number of subjects: 498
Study: 38753448

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 3274
Study: 38753452

Group type: EXPERIMENTAL
Intervention: Early initiation of direct oral anticoagulants
Number of subjects: 1970
Study: 38753528

Group type: EXPERIMENTAL
Intervention: Optical enhancement mode 2
Number of subjects: 2430

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 2430
Study: 38753616

Group type: EXPERIMENTAL
Intervention: Close Assessment and Testing for Chronic GVHD (CATCH) study intervention including clinician assessment, patient-reported outcomes, and multiple biospecimens collection.
Number of subjects: 0
Study: 38753757

Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical therapy using alpha emitters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel targets such as tumor-specific antigens, overexpressed receptors, and intracellular biomolecules
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha emitters
Number of subjects: 0
Study: 38753764

Group type: EXPERIMENTAL
Intervention: Remote live stream assessment of the North Star Ambulatory Assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person assessment of the North Star Ambulatory Assessment
Number of subjects: 0
Study: 38753813

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP) + single-dose azithromycin (AZ)
Number of subjects: 1319
Study: 38753869

Group type: EXPERIMENTAL
Intervention: High load (standing with weight vest weighing 11% of body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No load (sitting)
Number of subjects: 10
Study: 38754046

Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 77
Study: 38754056

Group type: EXPERIMENTAL
Intervention: Niraparib (200 or 300 mg once daily), Dostarlimab (500 mg once every 3 weeks for four 21-day cycles, followed by 1,000 mg once every 6 weeks), Bevacizumab (15 mg/kg once every 3 weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Niraparib, Dostarlimab, and Bevacizumab
Number of subjects: 41
Study: 38754068

Group type: EXPERIMENTAL
Intervention: Patient-centred monitoring (PCM)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Dual therapy (dolutegravir plus emtricitabine)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Monitoring options
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Renal function, lipids, glucose values, weight
Number of subjects: 187
Study: 38754101

Group type: EXPERIMENTAL
Intervention: Web-based psychological intervention incorporating cognitive behavioral therapy tools, diabetes self-care promotion, and mindfulness
Number of subjects: 49

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 49